 |
RSS
feed of Glycosmedia updates available via Twitter |
| |
To subscribe to RSS updates from the Twitter page
of Glycosmedia click on the link above (Editor) |
| |
|
|
Incretin-related
Therapies |
| |
Targeting the underlying physiology and cardiometabolic
factors of type 2 diabetes (Journal of Family Practice) |
| |
|
|
Use
of short-acting insulin aspart in managing older people with
diabetes |
| |
There is evidence that it improves postprandial
glucose control, improves long-term metabolic control, reduces
risk of major nocturnal hypoglycemia and increases patient satisfaction
compared with soluble insulin (Clinical Interventions in Aging) |
| |
|
|
Diabetes
Prevalence and Therapeutic Target Achievement in the United States,
1999 to 2006 |
| |
The prevalence of diagnosed diabetes increased
significantly from 1999 to 2006. The proportion of people with
diagnosed diabetes achieving glycemic and LDL targets also increased
(The American Journal of Medicine) |
| |
|
|
Launch
of landmark consensus report to help stop the growing type 2
diabetes epidemic in South and Central America |
| |
A pivotal consensus report, produced by the
International Diabetes Federation (IDF) South and Central America
region (SACA), which addresses the rising diabetes epidemic in
the region (IDF) |
| |
|
|
Blood
glucose monitoring – the underrated key to successful therapy |
| |
Bayer HealthCare Diabetes Care helps simplify
life for patients with diabetes and their health care providers
(Bayer) |
| |
|
|
Comparison
of continual insulin or secretagogue treatment in type 2 diabetic
patients with alternate insulin–secretagogue administration |
| |
Alternate insulin–secretagogue
treatment can effectively reduce HbA1c and help to improve islet
function with reduced risk of hypoglycemia and weight gain under
good compliance (Diabetes Research and Clinical Practice - via
Science Direct) |
| |
|
|
C-Peptide
Levels and Insulin Independence Following Autologous Nonmyeloablative
Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type
1 Diabetes Mellitus |
| |
After a mean follow-up of 29.8 months following
autologous nonmyeloablative HSCT in patients with newly diagnosed
type 1 DM, C-peptide levels increased significantly and the majority
of patients achieved insulin independence with good glycemic control
(JAMA) |
| |
|
|
Etanercept
Treatment in Children with New Onset Type 1 Diabetes: Pilot Randomized,
Placebo-Controlled, Double Blind Study |
| |
In this small pilot study, treatment of pediatric
patients newly diagnosed with type 1 diabetes mellitus with etanercept
resulted in lower HbA1c, increased endogenous insulin production,
suggesting preservation of beta cell function (Diabetes Care) |
| |
|
|
The
vascular actions of insulin control its delivery to muscle and
regulate the rate-limiting step in skeletal muscle insulin action |
| |
These findings highlight the need to further
understand the role of the vascular actions of insulin in metabolic
regulation (Diabetologia) |
| |
|
|
Reasons
of general practitioners for not prescribing lipid-lowering medication
to patients with diabetes: a qualitative study |
| |
Treatment quality could improve by addressing
issues, such as lack of knowledge or motivation of both the patient
and the GP (BMC Family Practice) |
| |
|
|
CIGNA
and Merck Sign Performance-Based Contract |
| |
Contract Promotes Medication Adherence to Better
Control Blood Sugar Levels for People with Type-2 Diabetes (Business
Wire) |
| |
|
|
Onglyza
delay but AstraZeneca’s Iressa set for EU return |
| |
AstraZeneca and Bristol-Myers Squibb have been
told by the US Food and Drug Administration that has pushed back
its decision date on their new diabetes drug Onglyza (PharmaTimes) |
| |
|
|
UPDATE
2-EU agency backs Novo's diabetes drug Victoza |
| |
Novo Nordisk's key new diabetes drug Victoza
received a significant boost on Thursday as European regulators
recommended its approval, three weeks after U.S. experts cast doubt
on its safety (Reuters) |
| |
|
|
Discontinuation
of Development of TAK-379 for Treatment of Diabetes |
| |
TAK-379 is an anti-diabetic agent categorized
as an insulin sensitizer and was in the phase 2 stage of development
in the U.S. and Europe, and in the phase 1 stage of development
in Japan respectively. However, Takeda has concluded that TAK-379’s profile does not meet the internal criteria to support continuation of further
development activities (PharmaLive) |
| |
|
|
BDA
Food Facts |
| |
Food Facts sheets to download and print for
your own reference (British Dietetic Association) |
| |
|
|
Mayo
Clinic Researcher Calls for “Evidence-Based About-Face” in Managing Type 2 Diabetes |
| |
Endocrinologist Victor Montori, M.D., and co-author
Mercè Fernández-Balsells, M.D, review evidence from several large randomized trials involving
patients with type 2 diabetes and conclude that current diabetes
treatment guidelines place inordinate emphasis on tight glucose
control (Mayo Clinic) |
| |
|
|
Acute
hyperinsulinemia decreases plasma osteoprotegerin with diminished
effect in type 2 diabetes and obesity |
| |
Acute hyperinsulinemia decreases plasma OPG,
but with diminished effect in individuals with type 2 diabetes
and obesity (European Journal of Endocrinology) |
| |
|
|
Experimental
Insulin-Like Growth Factor Receptor Inhibitor Reduced Pancreatic
Cancer Growth |
| |
Amgen are testing a fully human monoclonal antibody
that inhibits the activity of insulin-like growth factors (IGF-1
and IGF-2) and appears to reduce pancreatic cancer cells in early
testing (PharmaLive) |
| |
|
|
International
Diabetes Federation moves offices |
| |
The International Diabetes Federation (IDF)
today announced they have moved to new offices in Brussels (IDF) |
| |
|
|
AHP,
Nurse and Midwife Research Training Fellowship |
| |
These Fellowships are open to allied health
professionals, nurses and midwives who are committed to the care
of people with diabetes and their carers and who wish to undertake
training in clinical or basic science research at a UK Higher Education
institution leading to a PhD (Diabetes UK) |
| |
|
|
Visit us on Twitter and Facebook |
| |
|
| |
|
